Literature DB >> 20567130

[A case of ascending colon cancer with unresectable distant metastases treated by systemic chemotherapy].

Kiichi Sugimoto1, Yoshihiko Tashiro, Kiichi Nagayasu, Kouichiro Niwa, Seigo Ono, Shun Ishiyama, Masaki Hata, Hiromitsu Komiyama, Makoto Takahashi, Yukihiro Yaginuma, Yutaka Kojima, Michitoshi Goto, Masanobu Tanaka, Hironobu Sengoku, Atsushi Okuzawa, Yuichi Tomiki, Kazuhiro Sakamoto.   

Abstract

The patient, a male in his 70s, was referred to this hospital by his neighborhood doctor with what was said to be impaired hepatic function. Detailed examinations revealed a circumferential ascending colon cancer, diffuse hepatic metastases scattered over both liver lobes, and lymph node metastases in the left axilla. With the primary lesion-induced symptoms of stenosis controllable, the patient began systemic chemotherapy by mFOLFOX6 without a resection of the primary lesion. After completing a 10-course treatment, the patient underwent surgery to resect the primary lesion in preparation for bevacizumab treatment. In the postoperative systemic chemotherapy, FOLFIRI and mFOLFOX6 were administered concomitantly with bevacizumab. After a total of 19 courses, the patient's systemic condition gradually deteriorated. He eventually died of cancer one year and seven months after diagnosis of the primary lesion or one year and one month subsequent to the resection of the primary lesion. No consensus has been reached on the necessity to resect the primary lesion in patients with advanced colorectal cancer who also have unresectable distal metastases. Systemic chemotherapy, nevertheless, can provide tumor control on both primary and metastatic lesions and could become a treatment option in the future.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20567130

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  1 in total

Review 1.  Axillary Lymph Node Involvement, a Unique Pattern of Metastasis in BRAF-Mutant Colorectal Cancer.

Authors:  Marla D Lipsyc; Rona Yaeger; Lynn T Dengel; Leonard Saltz
Journal:  JAMA Oncol       Date:  2015-08       Impact factor: 31.777

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.